John Burke, MD Physician, Associate Chair, US Oncology Hematology Research Program, Medical Oncology/ Hematology, Rocky Mountain Cancer Centers discusses how physicians should be thinking about the use of BTK inhibitors in the treatment of CLL.
Advertisement